Evidence map›Paper›PMID 38238479›Full record

ArticleScientific reports2024

Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO

Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Lars-Olaf Cardell *Division of ENT Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0003-0538-9580
Thomas Sterner *Department of Economics, School of Business, Economics and Law, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-4771-3545
Waqas AhmedCovalence Research Ltd, Harpenden, UK.ORCID 0000-0002-9035-7614
Andreas Kallsoy SlættanesALK, Bøge Allé 1, DK-2970, Hørsholm, Denmark.
Mikael SvärdALK Nordic, Faktorvägen 9, SE-434 21, Kungsbacka, Sweden.
Richard F PollockCovalence Research Ltd, Harpenden, UK. pollock@covalence-research.com.ORCID 0000-0002-9873-7507
ALK-Abelló (Denmark) · DKA-T Society · GBCovalent Associates (United States) · USKarolinska Institutet · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Sweden, allergy immunotherapy (AIT) is available as either subcutaneous immunotherapy (SCIT) injections or sublingual immunotherapy (SLIT) tablets and is used to treat moderate-severe allergic rhinitis (AR). This study sought to determine treatment-related CO

Indexed as

Rhinitis, AllergicSublingual ImmunotherapyCarbon DioxideDesensitization, ImmunologicHumansSwedenTabletsTravelTravel-Related IllnessCarbon DioxideTablets

Identifiers

PMID38238479
PMCPMC10796394
OpenAlexW4390984639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.